NCT03606928View on ClinicalTrials.gov

mFLOT Chemotherapy as First-line Treatment in GC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

November 9, 2019

Study Completion Date

January 1, 2020

Conditions
Gastric Cancer
Interventions
DRUG

docetaxel, oxaliplatin, 5-FU, leucovorin

This is a single-arm study with all patients receiving mFLOT chemotherapy.

Trial Locations (1)

200025

Department of Oncology, Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT03606928 - mFLOT Chemotherapy as First-line Treatment in GC | Biotech Hunter | Biotech Hunter